Harvard Bioscience Inc.

Last updated September 27, 2026

Organization details

Legal name
Harvard Bioscience Inc.
Ownership
Public
Status
Active
Sector (GICS)
Information Technology
SIC code
3826 — Laboratory Analytical Instruments
Jurisdiction of incorporation
Delaware
Headquarters city
Holliston
Headquarters state / province
Massachusetts
Headquarters country
United States
Fiscal year end
December
Ticker symbol
HBIO
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001123494
EIN
04-3306140
Wikidata ID
Q16994890

Board of directors

Chief executives

James W. Green · Chief Executive Officer
Dates unknown
John D. Duke · Chief Executive Officer
Dates unknown

Director election results

Annual meeting of June 2, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

2 of this board's directors also sit on 6 other boards.

Network of Harvard Bioscience Inc.'s board connections Ashland Inc. Ashland Inc. Bone Biologics Corp Bone Biologics Corp Entegris Inc. Entegris Inc. ITT Inc. ITT Inc. Purple Biotech Ltd. Purple Biotech Ltd. Verastem Inc. Verastem Inc. Bertrand Loy Bertrand Loy Robert E. Gagnon Robert E. Gagnon Harvard Bioscience Inc.
Shared director Other board Same sector

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$202,354
5 purchases by 4 insiders
Sold, last 12 months
$0
0 sales by 0 insiders
Date Insider Transaction Shares Price Value
Jun 9, 2026 Katherine A. Eade Director Grant or award +16,556 — —
Jun 9, 2026 William Snider Director Grant or award +16,556 — —
Jun 9, 2026 Stephen J. Denelsky Director Grant or award +16,556 — —
Jun 9, 2026 Robert E. Gagnon Director Grant or award +16,556 — —
Jun 9, 2026 Seth Benjamin Benson Director Grant or award +16,556 — —
Mar 20, 2026 John D. Duke Director, Officer (Chief Executive Officer) Grant or award +75,000 — —
Mar 20, 2026 Frost Mark T Officer (Chief Financial Officer) Grant or award +30,000 — —
Mar 17, 2026 Stephen J. Denelsky Director Open-market purchase +10,000 $4.87 $48,700
Mar 17, 2026 William Snider Director Open-market purchase +8,475 $4.85 $41,104
Mar 16, 2026 William Snider Director Open-market purchase +12,525 $4.99 $62,500
Mar 16, 2026 John D. Duke Director, Officer (Chief Executive Officer) Open-market purchase +5,000 $5.01 $25,050
Mar 16, 2026 Frost Mark T Officer (Chief Financial Officer) Open-market purchase +5,000 $5.00 $25,000
Dec 17, 2025 William Snider Director Grant or award +110,000 — —
Sep 5, 2025 Stephen J. Denelsky Director Grant or award +110,000 — —
Aug 15, 2025 James W. Green Director Sold back to the company −49,048 — —

Organizations in the same sector, closest in location and size first.

Questions about Harvard Bioscience Inc.

Who is the CEO of Harvard Bioscience Inc.?

James W. Green is Harvard Bioscience Inc.'s Chief Executive Officer.

How many directors are on Harvard Bioscience Inc.'s board?

Harvard Bioscience Inc.'s board has 11 directors: Alan I. Edrick, Bertrand Loy, James W. Green, Jennifer Cote, John D. Duke, Katherine A. Eade, Robert E. Gagnon, Seth Benjamin Benson, Stephen J. Denelsky, Thomas W. Loewald and 1 other.

Are Harvard Bioscience Inc. insiders buying or selling shares?

Over the last 12 months, Harvard Bioscience Inc. insiders bought $202,354 of shares in 5 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="harvard-bioscience-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.